Original Article
Successful Use of Intravenous Dexmedetomidine for Magnetic Resonance Imaging Sedation in Autistic Children
Abstract
Objectives: Autism and autism spectrum disorders (A/ASD) represent a family of neurodevelopmental conditions that are associated with overactive, difficult-to-control behaviors. Sedating these patients for magnetic resonance imaging (MRI) poses challenges. Children with A/ASD were examined against clinical controls to determine the effectiveness and safety of intravenous (IV) dexmedetomidine for deep sedation.Methods: The quality assurance data on all of the children who received IV dexmedetomidine sedation for MRI between July 2007 and December 2012 were reviewed. Patients in both groups were sedated by an intensivist-based team with a standard plan of 2 μg/kg IV dexmedetomidine administered for 10 minutes followed by an infusion of 1 μg · kg −1 · hour −1 . The amount of IV dexmedetomidine was titrated to the deep level of sedation. A total of 56 patients in the A/ASD group and 107 in the control group were sedated with no reported sedation failures. Sedation parameters were compared between the A/ASD and control groups using analysis of covariance models, controlling for age, sex, and weight.
Results: Children in the A/ASD group were predominantly male (73%) and older (6.1 ± 0.3 years) than children in the control group (56%; 5.0 ± 0.2 years; P < 0.05 for both). Procedure time was significantly shorter for patients in the A/ASD group than in control patients (34.6 ± 2.4 vs 44.3 ± 1.6 minutes; P < 0.05). The A/ASD and control groups required a similar IV bolus of dexmedetomidine (2.6 μg/kg ± 0.1 vs 2.4 μg/kg ± 0.10; P = 0.29), with a significantly lower infusion dose in the A/ASD group (0.74 μg/kg ± 0.05 vs 0.89 μg/kg ± 0.03; P < 0.05). Heart rates were similar in the A/ASD group and the control group (67.0 beats per minute ± 1.6 vs 69.3 ± 1.1 beats per minute; P = 0.250). There were no complications. Recovery time was approximately 7 minutes longer in the A/ASD group than in the control group, but this was nonsignificant (101.2 ± 3.5 minutes vs 94.2 ± 2.4 minutes; P = 0.12). Analyses were performed using analysis of covariance methods and generalized linear models to control for age, sex, and weight.
Conclusions: Children with A/ASD can be successfully sedated for MRIs with IV dexmedetomidine without complications.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
2. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005;162:1133-1141.
3. Mehta UC, Patel I, Castello FV. EEG sedation for children with autism. J Dev Behav Pediatr 2004;25:102-104.
4. Van der Walt JH, Moran C. An audit of perioperative management of autistic children. Paediatr Anaesth 2001;11:401-408.
5. Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paeditric Anaesth 2008:18:403-411.
6. Marti-Bonmati L, Ronchera-Ohms CL, Casilas C, et al. Randomized double-blind clinical trial of intermediate- versus high-dose chloral hydrate for neuroimaging of children. Neuroradiology 1995;7:687-691.
7. Ronchera-Oms CL, Casillas C, Martí-Bonmatí L, et al. Oral chloral hydrate provides effective and safe sedation in paediatric magnetic resonance imaging. J Clin Pharm Ther 1994;19:239-243.
8. Hubbard AM, Markowitz RI, Kimmel B, et al. Sedation for pediatric patients undergoing CT and MRI. J Comput Assist Tomogr 1992;16:3-6.
9. Audenaert SM, Montgomery CL, Thompson DE, et al. A prospective study of rectal methohexital: efficacy and side effects in 648 cases. Anesth Analg 1995;81:957-961.
10. Strain JD, Campbell JB, Harvey LA, et al. IV nembutal: safe sedation for children undergoing CT. AJR Am J Roentgenol 1988;151:975-979.
11. Manuli MA, Davies L. Rectal methohexital for sedation of children during imaging procedures. AJR Am J Roentgenol 1993;160:577-580.
12. Short SM, Aun CS. Haemodynamic effects of propofol in children. Anaesthesia 1991;46:783-785.
13. Dyck JB, Shafer SL. Dexmedetomidine pharmacokinetics and pharmacodynamics. Anesth Pharmacol Rev 1993;1:238-245.
14. Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs 2008;10:49-69.
15. Koroglu A, Demirbilek S, Teksan H, et al. Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results. Br J Anaesth 2005;94:821-824.
16. Berkenbosch JW, Wankum PC, Tobias JD. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Pediatr Crit Care Med 2005;6:435-439.
17. Koroglu A, Teksan H, Sagir O, et al. A comparison of the sedative, hemodynamic and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg 2006;103:63-67.
18. Mason KP, Zgleszewski SE, Dearden JL, et al. Dexmedetomidine for pediatric sedation for computed tomography imaging studies. Anesth Analg 2006;103:57-62.
19. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002;96:1004-1017.
20. American Academy of Pediatrics, American Academy of Pediatric Dentistry, Coté CJ, Wilson S, Work Group on Sedation. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics 2006;118:2587-2602.
21. Mathers LH, Frankel LR. Pediatric emergencies and resuscitation. In: Kliegman RM, Behrman RE, Jenson HB, et al., eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: Elsevier; 2007:387-404.
22. Rainey L, van der Walt JH. The anesthetic management of autistic children. Anaesth Intens Care 1998;26:682-686.
23. Seid M, Sherman M, Seid AB. Perioperative psychosocial interventions for autistic children undergoing ENT surgery. Int J Pediatr Otorhinolaryngol 1997;40:107-113.
24. Rapin I. Autism. N Engl J Med 1997;337:97-104.
25. American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007;120:1162-1182.
26. Tuchman R. Treatment of seizure disorders and EEG abnormalities in children with autism spectrum disorders. J Autism Dev Disord 2000;30:485-489.
27. Canitano R, Luchetti A, Zappella M. Epilepsy, electroencephalographic abnormalities, and regression in children with autism. J Child Neurol 2005;20:27-31.
28. Council on Children With Disabilities, Section on Developmental Behavioral Pediatrics, Bright Futures Steering Committee, Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. Pediatrics 2006;118:405-420.
29. Gurstein HB, Johnson KL, Heard MB, et al. Oral ketamine preanesthetic medication in children. Anesthesiology 1992;76:28-33.
30. Donahue PJ, Dineen PS. Emergence delirium following oral ketamine. Anesthesiology 1992;77:604-605.
31. Frush DP, Bisset GS3rd, Hall SC. Pediatric sedation in radiology: the practice of safe sleep. AJR Am J Roentgenol 1996;167:1381-1387.
32. Mason KP, Zurakowski D, Karian VE, et al. Sedatives used in pediatric imaging: comparison of IV pentobarbital with IV pentobarbital with midazolam added. AJR Am J Roentgenol 2001;177:427-430.
33. Karian VE, Burrows PE, Zurakowski D, et al. Sedation for pediatric radiologic procedures: analysis of potential causes of sedation failure and paradoxical reactions. Pediatr Radiol 1999;29:869-873.
34. Karian VE, Burrows PE, Zukarowski D, et al. The development of a pediatric radiology sedation program. Pediatr Radiol 2002;32:348-353.
35. Malviya S, Voepel-Lewis T, Tait AR, et al. Pentobarbital versus chloral hydrate for sedation of children undergoing MRI: efficacy and recovery characteristics. Paediatr Anaesth 2004;14:589-595.
36. Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000;90:699-705.
37. Tobias JD, Berkenbosch JW. Initial experience with dexmedetomidine in paediatric-aged patients. Paediatr Anaesth 2002;12:171-175.
38. Tobias JD, Berkenbosch JW, Russo P. Additional experience with dexmedetomidine in pediatric patients. South Med J 2003;96:871-875.
39. Triltsch AE, Welte M, Von Homeyer P, et al. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med 2002;30:1007-1014.
40. Dutta S, Karol MD, Cohen T, et al. Effect of dexmedetomidine on propofol requirements in healthy subjects. J Pharm Sci 2001;90:172-181.
41. Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders. Pediatr Neurol 2009;41:88-94.
42. Heard CM, Joshi P, Johnson K. Dexmedetomidine for pediatric MRI sedation: a review of a series of cases. Paediatr Anaesth 2007;17:888-892.
43. Cravero JP, Blike GT, Beach M. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics 2006;118:1087-1096.
